01 Sep 2015 Geneva, Switzerland, 01 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs…
Category: Press release
The press releases from ObsEva
ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study – Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women –
Geneva, Switzerland, 23 June 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour – Positive Safety, Rapid Absorption and Absence of Interaction with Betamethasone is Basis for Phase 2 Study –
Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
ObsEva Announces the Initiation of a Pivotal Phase 2 Study to Evaluate OBE001 for Improving Embryo Implantation and Clinical Pregnancy Rate in Women Undergoing IVF/ICSI
Geneva, Switzerland, 18 November 2014 – ObsEva, a Swiss biopharmaceutical company dedicated to the development and commercialization of innovative drugs…
ObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development
Geneva, Switzerland, 10 September 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative…
ObsEva SA announced today it was granted JEDI status and European SME status
Geneva, Switzerland, 23 July 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for…
ObsEva SA Announces Appointments to its Board of Directors and Scientific Advisory Board
Geneva, Switzerland, 17 January 2014 – ObsEva, a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for…
ObsEva SA announces CHF 32 Million Series A funding from leading Venture Capital firms and a license agreement with MerckSerono
Geneva, Switzerland, 29 August 2013 – ObsEva today announced the closing of a CHF 32 million Series-A financing round (€25.6 million)….